Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Inhaled Medications

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Upper Respiratory Drugs: Decongestants

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Drugs Used in Upper Respiratory Disorders: Overview

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19.

Infectious diseases and therapy·2026

Same author

Association and correlation of patient symptom perception and asthma control - a rapid literature review.

Asian Pacific journal of allergy and immunology·2024

Same author

Exploring Clinical Remission in Moderate Asthma - Perspectives from Asia, the Middle East, and South America.

Pulmonary therapy·2024

Same author

Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air<sup>®</sup> approach.

Clinical and translational allergy·2023

Same author

Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities.

Clinical and translational allergy·2022

Same author

Consensus on mild asthma management: results of a modified Delphi study.

The Journal of asthma : official journal of the Association for the Care of Asthma·2022

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

Ciclesonide, a hypotonic intranasal corticosteroid.

Hugo Neffen¹, Mark A Wingertzahn

¹Respiratory Medicine Unit, Children's Hospital Orlando Alassia, Santa Fe, Argentina. hugoneffen@arnet.com.ar

Allergy and Asthma Proceedings

|June 19, 2010

Summary

Ciclesonide nasal spray offers effective relief for moderate to severe allergic rhinitis (AR) in adults and children. This intranasal corticosteroid (INCS) has a favorable safety profile and rapid onset of action, improving quality of life.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

Allergology and Immunology
Pharmacology
Otorhinolaryngology

Background:

Intranasal corticosteroids (INCSs) are first-line treatments for moderate to severe allergic rhinitis (AR).
Ciclesonide is a recently approved INCS with a unique formulation designed to enhance efficacy and patient experience.
Excipients in some INCSs can negatively impact nasal function; ciclesonide's formulation avoids these.

Purpose of the Study:

To evaluate the efficacy and safety of ciclesonide nasal spray for treating allergic rhinitis.
To assess the pharmacokinetic profile and potential systemic effects of intranasal ciclesonide.
To determine the onset of action and long-term safety of ciclesonide in various patient populations.

Main Methods:

Clinical trials involving pediatric, adolescent, and adult patients with seasonal and perennial AR.
Environmental exposure unit studies to assess onset of action.
Pharmacokinetic assessments and evaluation of hypothalamic-pituitary-adrenal axis function.

Main Results:

Ciclesonide nasal spray demonstrated efficacy in reducing AR symptoms and improving quality of life for up to one year.
The drug showed a rapid onset of action, with effects observed as early as 1 hour post-administration.
Low systemic exposure, no significant cortisol suppression as monotherapy, and an acceptable safety profile were observed, even in children as young as 2 years.

Conclusions:

Intranasal ciclesonide is an effective and safe treatment option for moderate to severe allergic rhinitis in a broad age range.
Its formulation offers advantages over other INCSs, including optimized absorption and reduced sensory irritation.
Ciclesonide provides a valuable new therapeutic choice for managing AR symptoms and enhancing patient well-being.